Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AV078
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Hevolution Foundation
Deal Size : $50.0 million
Deal Type : Financing
Aeovian Doses First Participants in Phase 1 Trial, Raises $50 Million Financing
Details : Proceeds will support AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor, with Phase 2 trials planned for adult and pediatric patients suffering from TSC refractory epilepsy.
Product Name : AV078
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 28, 2024
Lead Product(s) : AV078
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Hevolution Foundation
Deal Size : $50.0 million
Deal Type : Financing